Filing Flows

Filing Flows › Companies › Pharma-Bio Serv › Cash flow

Pharma-Bio Serv cash flow, quarter by quarter

Latest: Q3 FY26 · from the cash-flow statements filed with the SEC

Free cash flow$60K in Q3 FY26 · −$421K over twelve months

Operating cash flow$61K
Capital spending−$1K
Free cash flow+$60K
Cash conversion cycle48 days

Analysis

In Q3 FY26, Pharma-Bio Serv generated $61K of operating cash flow and spent $1K on capital projects, leaving free cash flow of $60K. That is $175K less than in Q3 FY25 ($234K).

Over the twelve months to Jul 31, 2026, operating cash flow was −$415K; the largest uses were dividends ($1.7M), operating cash flow ($415K), other investing ($297K); the cash balance fell by $2.4M.

Operating cash flow was $61K against net income of −$14K. The largest differences: receivables +$296K, prepaid and other assets −$142K, depreciation & amortization +$14K.

Its cash conversion cycle was 48 days (receivables 101 + inventory 0 − payables 53).

Free cash flow

Pharma-Bio Serv: free cash flow by quarterPharma-Bio Serv: free cash flow by quarter−$79KQ4 FY24−$429KQ1 FY25−$306KQ2 FY25$234KQ3 FY25$279KQ4 FY25−$393KQ1 FY26−$368KQ2 FY26$60KQ3 FY26
Operating cash flow less capital spending.
Pharma-Bio Serv: operating cash flow against capital spendingPharma-Bio Serv: operating cash flow against capital spendingOperating cash flowCapital spending$78K$157KQ4 FY24−$429K$0Q1 FY25−$302K$4KQ2 FY25$237K$2KQ3 FY25$280K$350Q4 FY25−$390K$2KQ1 FY26−$365K$2KQ2 FY26$61K$1KQ3 FY26
Latest (Q3 FY26): Operating cash flow $61K, Capital spending $1K.

Capital allocation, year by year

Pharma-Bio Serv: where the cash came from (up) and went (down), by fiscal yearPharma-Bio Serv: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedAsset salesCapital spendingBuybacksDividendsFY21: Operating cash flow $805KFY21: Shares issued $2FY21: Asset sales $58KFY21: Capital spending −$11KFY21: Buybacks −$26KFY21: Dividends −$1.7M$862KFY21FY22: Operating cash flow $592KFY22: Shares issued $3FY22: Capital spending −$19KFY22: Buybacks −$82KFY22: Dividends −$3.4M$592KFY22FY23: Operating cash flow $1.9MFY23: Shares issued $5FY23: Capital spending −$7KFY23: Buybacks −$34KFY23: Dividends −$1.7M$1.9MFY23FY24: Operating cash flow −$567KFY24: Capital spending −$160KFY24: Buybacks −$11KFY24: Dividends −$1.7MFY24FY25: Operating cash flow −$215KFY25: Capital spending −$7KFY25: Buybacks −$31KFY25: Dividends −$1.7MFY25
Over these 5 years operating cash flow totalled $2.5M; the largest uses were dividends ($10.3M) and operating cash flow ($782K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$8.6M
Debtnone
Net cash$8.6M
Cash runwaymore than 10 years

Pharma-Bio Serv is burning cash: its operations consume cash, a free cash flow of −$421K a year at the current rate against $8.6M of cash and investments: a runway of more than ten years at that rate before any new financing.

Where the cash came from and went

Pharma-Bio Serv: sources (+) and uses (−) of cash, Q3 FY26Pharma-Bio Serv: sources (+) and uses (−) of cash, Q3 FY26Other investing−$325KCash drawn (+) / kept (−)$273KOperating cash flow$61KExchange rates−$8KCapital spending−$1K
Pharma-Bio Serv: sources (+) and uses (−) of cash, TTM to Q3 FY26Pharma-Bio Serv: sources (+) and uses (−) of cash, TTM to Q3 FY26Cash drawn (+) / kept (−)$2.4MDividends−$1.7MOperating cash flow−$415KOther investing−$297KBuybacks−$12KExchange rates$8KCapital spending−$6K

From profit to cash

Pharma-Bio Serv: net income to operating cash flow, Q3 FY26Pharma-Bio Serv: net income to operating cash flow, Q3 FY26Net income−$14KDepreciation & amortization$14KStock-based pay$9KReceivables$296KPrepaid and other assets−$142KOperating cash flow$61K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 FY26101—5348
Q2 FY2689—4643
Q1 FY26101—5446
Q4 FY2594—6132
Q3 FY25110—6050
Q2 FY2599—5346
Q1 FY2597—5640
Q4 FY24101—6437

Every quarter

QuarterOperating cash flowCapital spendingBuybacksDividendsCash drawn (+) / kept (−)Free cash flow
Q3 FY26$61K−$1K——$273K$60K
Q2 FY26−$365K−$2K−$1K−$1.7M$4.0M−$368K
Q1 FY26−$390K−$2K−$2K—−$2.4M−$393K
Q4 FY25$280K−$350−$9K—$579K$279K
Q3 FY25$237K−$2K−$5K—−$1.9M$234K
Q2 FY25−$302K−$4K−$17K−$1.7M$5.2M−$306K
Q1 FY25−$429K———−$540K−$429K
Q4 FY24$78K−$157K——−$247K−$79K

Pharma-Bio Serv: income statement and cash flow

Pharma-Bio Serv, Q3 FY26: revenue $2.3M (+19% year over year), operating margin -3.1%. The chart follows the revenue to costs, profit and cash.

Pharma-Bio Serv: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.